消化器官系统领域的合作与授权协议（2016-2026）

消化器官系统领域併购的决定性指标

消化器官系统领域的合作涵盖了广泛的适应症、治疗方法和研发阶段，其交易结构反映了该领域疾病领域和治疗方法的多样性。

本报告对消化器官系统领域的 432 项合作与许可协议进行了全面系统的分析，清楚地展示了整个市场合作的设计、谈判和执行方式，并以证据为基础进行了阐述。

清楚了解市场标准

本报告将帮助您准确了解消化系统交易的实际结构，并使您能够：

• 自信地对标类似交易
• 对相关交易中的预付款、里程碑付款和特许权使用费结构进行详细分析。
• 设定切合实际的市场参数
• 您可以深入了解交易条款如何因阶段、资产类型和合作伙伴情况而异。
• 支持实证评估和结构性决策
• 我们将根据实际交易数据进行内部讨论，而不是根据假设。
• 了解主要企业如何进行交易。
• 在日益多元化和不断发展的治疗领域中，可视化合作伙伴的行为和重复交易结构。
• 全面了解交易结构和执行情况
• 本报告超越了表面的交易数据，提供了对底层合约文件的访问，使您能够详细了解实际合约是如何构建的。

这包括：

• 授予和保留的权利
• 负责开发和商业化
• 财务结构和支付触发机制
• 关键合约条款和保障措施
• 这种程度的透明度对于了解消化器官系统合作中价值、风险和控制是如何分配的至关重要，尤其是在慢性疾病和多样化的疾病环境中。
• 专为实际业务发展和策略制定而设计。

本报告广泛用于以下用途：

• 建置和基准测试实际交易
• 在清晰的市场环境下准备谈判
• 合作机会及目的地评估
• 支援稳健且引人注目的数据驱动型内部策略
• 内容
• 432项消化器官系统领域的合作与授权协议
• 财务条款，包括预付款、里程碑付款和版税（如有揭露）。
• 可全文搜寻的合约目录（依公司、治疗领域及技术分类）
• 可直接查阅向美国证券交易委员会提交的合约和原始文件。
• 分析交易趋势、重大交易和活跃的交易商。
• 关于胃肠道领域交易的可靠、基于证据的参考资料。
• 本报告结合全面的交易报告和合约层面的深入分析，为如何在胃肠病学领域建立、谈判和评估合作伙伴关係提供了可靠的、基于证据的参考资料。

目录

执行摘要

第一章：引言

第二章：消化器官系统交易趋势

• 介绍
• 在消化器官系统领域长期合作
• 消化器官系统领域的合伙企业（按交易类型划分）
• 消化器官系统领域的合作（按产业划分）
• 消化器官系统领域的合作（依发展阶段划分）
• 消化器官系统领域的合作（按技术类型划分）
• 在消化器官系统领域进行合作（依治疗适应症划分）

第三章消化器官系统协作中的财务交易条款

• 介绍
• 消化器官系统合作的财务条款将予以披露。
• 消化器官系统协作的关键价值观
• 预付胃肠道治疗费用
• 消化器官系统相关合约的里程碑付款
• 消化器官系统专利费率

第四章：消化器官系统领域的主要交易和相关人员

• 介绍
• 在消化器官系统合作领域最活跃的公司
• 消化器官系统领域交易最活跃的公司名单
• 肠胃产品超值优惠（依价格排序）

第五章：消化器官系统合约文件清单

• 介绍
• 与消化器官系统相关的合作协议（如有）

第六章：基于治疗标靶的胃肠道药物交易

• 介绍
• 消化器官系统治疗标靶交易
• 特价优惠列表
• 特价优惠清单 - 各公司提供的消化器官系统相关产品特价优惠 (AZ)
• 交易清单 -消化器官系统相关交易（依技术类型分类）
• 交易类型的定义
• 关于这家研究公司
• Current Partnering
• 目前合约
• 理想合作伙伴最新报告的标题

The definitive benchmark for gastrointestinal dealmaking

Gastrointestinal partnering spans a broad range of indications, modalities, and stages of development, with deal structures reflecting the diversity of disease areas and therapeutic approaches across the space.

This report provides a comprehensive and structured analysis of 432 gastrointestinal collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how gastrointestinal deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by stage, asset type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a diverse and evolving therapeutic landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within gastrointestinal partnerships, particularly across chronic and heterogeneous disease settings.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark live transactions
• Prepare for negotiations with well-defined market context
• Evaluate partnership opportunities and counterparties
• Support internal strategy with robust, defensible data
• What's included
• 432 gastrointestinal collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy, and technology)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for gastrointestinal dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how gastrointestinal partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in gastrointestinal dealmaking

• 2.1. Introduction
• 2.2. Gastrointestinal partnering over the years
• 2.3. Gastrointestinal partnering by deal type
• 2.4. Gastrointestinal partnering by industry sector
• 2.5. Gastrointestinal partnering by stage of development
• 2.6. Gastrointestinal partnering by technology type
• 2.7. Gastrointestinal partnering by therapeutic indication

Chapter 3 - Financial deal terms for gastrointestinal partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for gastrointestinal partnering
• 3.3. Gastrointestinal partnering headline values
• 3.4. Gastrointestinal deal upfront payments
• 3.5. Gastrointestinal deal milestone payments
• 3.6. Gastrointestinal royalty rates

Chapter 4 - Leading gastrointestinal deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in gastrointestinal partnering
• 4.3. List of most active dealmakers in gastrointestinal
• 4.4. Top gastrointestinal deals by value

Chapter 5 - Gastrointestinal contract document directory

• 5.1. Introduction
• 5.2. Gastrointestinal partnering deals where contract document available

Chapter 6 - Gastrointestinal dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by gastrointestinal therapeutic target
• Deal directory
• Deal directory - Gastrointestinal deals by company A-Z
• Deal directory - Gastrointestinal deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Gastrointestinal partnering since 2016
• Figure 2: Gastrointestinal partnering by deal type since 2016
• Figure 3: Gastrointestinal partnering by industry sector since 2016
• Figure 4: Gastrointestinal partnering by stage of development since 2016
• Figure 5: Gastrointestinal partnering by technology type since 2016
• Figure 6: Gastrointestinal partnering by indication since 2016
• Figure 7: Gastrointestinal deals with a headline value
• Figure 8: Gastrointestinal deals with upfront payment values
• Figure 9: Gastrointestinal deals with milestone payment
• Figure 10: Gastrointestinal deals with royalty rates
• Figure 11: Active gastrointestinal dealmaking activity since 2016
• Figure 12: Top gastrointestinal deals by value since 2016